ClinicalTrials.gg
RecruitingNCT06987279Updated May 23, 2025

Lactobacillus Plantarum and Hormonal Regulation in Obese Women

An interventional study of Probiotic and Maltodextrin in Obesity, Women, sponsored by Wecare Probiotics Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by Wecare Probiotics Co., Ltd. · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing probiotic in Obesity — 9 open to participants now, 12 under way, none of them phase 3. Probiotic · Obesity.

Planned enrollment
10th of 33
100 · median 76
Started
2025
with 9 others
No phase
28 of 33
7 open now
Primary completion
2025-09
later than 3 of 11 live
Registered
27th of 33
by date
Lead sponsor
7 of 33
Wecare Probiotics Co., Ltd.

Among the 33 studies testing probiotic in Obesity, this one is the 10th largest by planned enrollment, is one of 10 that started in 2025, is one of 28 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 27th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 33 studies testing probiotic in Obesity are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About probiotic

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing probiotic in Obesity, or all of them as a file.
02

Study summary

To evaluate the regulatory effect of Lactobacillus plantans Lp90 formula on visceral fat metabolism and sex hormone balance in obese women.

03

Conditions studied

  • Obesity, Women

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 40 years old, female, ≥ 25 kg/m2.
  2. Be willing to receive follow-up during the intervention period.
  3. Be willing to provide two blood, urine and fecal samples during the intervention period.
  4. Be willing to take the compound probiotics by oneself every day during the intervention period.
  5. Have good hearing and be able to hear and understand all instructions during the intervention period.

Exclusion criteria

-

Exclusion Criteria:

  1. Suffering from digestive system diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease).
  2. Suffering from severe neurological disorders (epilepsy, stroke, severe head trauma, meningitis within the past 10 years, brain surgery, brain tumor, long-term coma - excluding general anesthesia).
  3. Have received/are currently receiving treatment for the following mental illnesses: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder.
  4. Take medication for depression or low mood.
  5. Suffering from internal organ failure (such as heart, liver or kidney failure, etc.).
  6. Have received radiotherapy or chemotherapy in the past.
  7. Have received general anesthesia surgery/procedures within the past three years, or plan to receive general anesthesia procedures/surgeries within the next three months during this trial.
  8. Have suffered from hepatitis (, ), or syphilis in the past.

    -

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Probiotic Group

    Take Lactobacillus plantarum Lp90 at 30 billion CFU per day.

    Dietary Supplement: Probiotic

  • Placebo comparator
    Placebo Group

    Taking maltodextrin 3 g/day.

    Dietary Supplement: Maltodextrin

Interventions

  • Dietary supplementProbiotic

    The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).

  • Dietary supplementMaltodextrin

    The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).

06

What researchers measure

Primary outcomes

  1. The changes of estradiol before and after the intervention

    The serum estrogen content of the subjects before and after the intervention was detected by enzyme-linked immunosorbent assay.

    Time frame: 0, 1, 2, 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Sep 2025, 3 months later.

Of 164 industry-sponsored interventional studies with no phase under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's planned 3 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
May 23, 2025
StartEst.
Jun 10, 2025
Primary completionEst.
Sep 10, 2025
CompletionEst.
Dec 10, 2025
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06987279
Responsible party
Sponsor
First posted
May 23, 2025
Start date
Jun 10, 2025 (estimated)
Primary completion
Sep 10, 2025 (estimated)
Completion
Dec 10, 2025 (estimated)
Last update
May 23, 2025

Study contacts

Yingpeng Tian, Doctor
Contact
tianyingpeng2021@163.com
13671979116 ext. +86

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion